In conclusion, our results indicate that inhibition of Foxp3, by inhibiting Treg function and promoting antitumor activity in BRCA cells, could facilitate not only the efficacy of immunotherapeutic strategies but could also improve the response to chemotherapy in BRCA. Here, FOXP3 is linked to invasive breast carcinoma.